GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Callan JMB CJMB · USD

Industrials · US listing · 🇺🇸 United States

Compare

0.30

+5.99%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Callan JMB

From its filings with the US Securities and Exchange Commission

SEC filings

Callan JMB is based in Spring Branch, Texas and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker CJMB. The SEC classifies its business as business services, nec. In the fiscal year to 31 December 2025, it reported revenue of $5.7m and a net loss of $8.0m. At that date it held total assets of $5.8m and shareholders' equity of $2.3m.

Read the filing on SEC.gov ↗

Company facts

Sector
Industrials
Industry
Air Freight & Logistics
Listed since
5 Feb 2025
Employees
10
Head office
244 FLIGHTLINE DRIVE, SPRING BRANCH, TX, 78070
Incorporated in
NV
Classification
Services-Business Services, NEC
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Wayne WilliamsChairman of the Board, President, Chief Executive Officer, Founder, since 2025$3.0m
  • Ms. Shannon BadgerInterim Chief Financial Officer
  • Mr. Eric KashExecutive Vice President, Director, since 2024$102,885
  • Dr. David CroyleChief Medical Officer$832,063
  • Sen. Gerald DialIndependent Director
  • Ms. Liberty DukeIndependent Director
  • Mr. Mark MellerIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Vertically integrated logistics solutions for life sciences industry with proprietary packaging and cold chain knowhow.
  • Ship2Q ultraviolet disinfection process ensures thermal reliability and cleanliness of system components.
  • Provides comprehensive alternatives for frozen shipping in life sciences industry including vaccines and biopharmaceuticals.

Weaknesses

  • Limited to 10 full-time employees and US-based operations.
  • IPO listed on 5 February 2025 with no prior market presence.
  • Operates only in Air Freight & Logistics industry without diversification.

Opportunities

  • Expansion into global markets for cryogenic shipping solutions in life sciences.
  • Growing demand for personalized medicine and cell therapies requiring cold chain logistics.
  • Partnerships with biopharmaceutical companies for specialized frozen shipping services.

Threats

  • Competition from established logistics providers in the US market.
  • Regulatory changes affecting cold chain logistics for life sciences.
  • Economic downturns impacting biopharmaceutical industry investments.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.